Marcelo Pacheco da Silva Junior

Marcelo Pacheco da Silva Junior

Auto-generated profile, based on publicly available information

Marcelo Pacheco da Silva Junior

Federal University of Rio de Janeiro

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2017 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
MMManuel Mendizabal
Manuel Mendizabal
LHLeila Haddad
Leila Haddad
PGPatricia E. Gallardo
Patricia E. Gallardo
AFAlejandro Ferrada
Alejandro Ferrada
ASAlejandro A. Soza
Alejandro A. Soza
MSMarcelo O. Silva
Marcelo O. Silva
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real‐clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real‐world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child‐Pugh B at baseline and one patient died due to multi‐organ failure. Follow up HCV‐RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child‐Pugh A cirrhosis in non‐European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child‐Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.

7 June 2025
Verified
Book Chapter
Closed access
PDF file
MJMarcelo Pacheco da Silva Junior
Marcelo Pacheco da Silva Junior
GLGabriel Ignácio dos Santos Pereira Lima
Gabriel Ignácio dos Santos Pereira Lima
Bruno GomesBruno Gomes
Bruno Gomes
AAAmanda Lorena Dantas de Aguiar
Amanda Lorena Dantas de Aguiar
ALAlexandre Landesmann
Alexandre Landesmann
RFRomildo Dias Toledo Filho
Romildo Dias Toledo Filho